Responsiveness of the 2024–2030 ACMT Research Agenda to New Funding Priorities and Research Environment
Journal of Medical Toxicology · 2026-07 · 22 (3) · 347-350
DOI: 10.1007/s13181-026-01138-4 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Medical Toxicology, online erschienen am 28.04.2026. Verfasst von Rachel Culbreth und 5 weiteren Autor:innen. Beteiligte Einrichtung: American College of Medical Toxicology, Phoenix, AZ, 85028, USA. Rachel.Culbreth@acmt.net. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- American College of Medical Toxicology, Phoenix, AZ, 85028, USA. Rachel.Culbreth@acmt.net.
- University of Illinois at Chicago, Chicago, IL, USA.
- UMass Chan Medical School, Worcester, MA, 01655, USA.
- Cook County Health, Chicago, IL, 60612, USA.
- American College of Medical Toxicology, Phoenix, AZ, 85028, USA.
- Georgetown University School of Medicine, Washington, DC, 20010, USA.
Zitieren
APA
Culbreth, R., Chhabra, N., Carreiro, S., Mycyk, M. B., Wax, P., & Mazer-Amirshahi, M. (2026). Responsiveness of the 2024–2030 ACMT Research Agenda to New Funding Priorities and Research Environment. Journal of Medical Toxicology, 22(3), 347-350. https://doi.org/10.1007/s13181-026-01138-4
Vancouver
Culbreth R, Chhabra N, Carreiro S, Mycyk MB, Wax P, Mazer-Amirshahi M. Responsiveness of the 2024–2030 ACMT Research Agenda to New Funding Priorities and Research Environment. Journal of Medical Toxicology. 2026;22(3):347-350. doi:10.1007/s13181-026-01138-4
BibTeX
@article{Culbreth2026,
author = {Culbreth, Rachel and Chhabra, Neeraj and Carreiro, Stephanie and Mycyk, Mark B and Wax, Paul and Mazer-Amirshahi, Maryann},
title = {Responsiveness of the 2024–2030 ACMT Research Agenda to New Funding Priorities and Research Environment},
journal = {Journal of Medical Toxicology},
year = {2026},
volume = {22},
number = {3},
pages = {347--350},
doi = {10.1007/s13181-026-01138-4}
}
EUVIMED